CHEK2 and neoplasm: In a recent retrospective case-control study, finally, Bergstrom and colleagues [17] found that BC patients with germline pathogenic variants of ATM, CHEK2, or PALB2 have an increased family history of breast cancer, tumor size >2.0 cm at the time of diagnosis, and potentially an increased risk of recurrence compared to mutation-negative patients.